| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
All eyes on the EuroNet-PHL-C1 trial for paediatric classical Hodgkin lymphoma
|
Metzger, Monika L
|
|
|
23 |
1 |
p. 11-13
|
artikel
|
| 2 |
Alternative analysis of the data from a HPV vaccine study in India
|
Sasieni, Peter
|
|
|
23 |
1 |
p. e9
|
artikel
|
| 3 |
Alternative analysis of the data from a HPV vaccine study in India – Authors' reply
|
Basu, Partha
|
|
|
23 |
1 |
p. e10
|
artikel
|
| 4 |
Assessment of tumour-agnostic therapies in basket trials
|
Popat, Sanjay
|
|
|
23 |
1 |
p. e7
|
artikel
|
| 5 |
Assessment of tumour-agnostic therapies in basket trials
|
Collignon, Olivier
|
|
|
23 |
1 |
p. e8
|
artikel
|
| 6 |
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
|
Jacobson, Caron A
|
|
|
23 |
1 |
p. 91-103
|
artikel
|
| 7 |
Build Back Better Act could affect US community-based oncology practices
|
Das, Manjulika
|
|
|
23 |
1 |
p. 19
|
artikel
|
| 8 |
Burden of cancer in adolescents and young adults
|
Saab, Raya
|
|
|
23 |
1 |
p. 2-3
|
artikel
|
| 9 |
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
|
Usmani, Saad Z
|
|
|
23 |
1 |
p. 65-76
|
artikel
|
| 10 |
CAR T-cell therapy for indolent lymphoma: a new treatment paradigm?
|
Holtzman, Noa G
|
|
|
23 |
1 |
p. 6-8
|
artikel
|
| 11 |
Clinical advances in PET–MRI for breast cancer
|
Fowler, Amy M
|
|
|
23 |
1 |
p. e32-e43
|
artikel
|
| 12 |
Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study
|
Trépo, Eric
|
|
|
23 |
1 |
p. 161-171
|
artikel
|
| 13 |
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma?
|
Correale, Pierpaolo
|
|
|
23 |
1 |
p. e13
|
artikel
|
| 14 |
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply
|
Fennell, Dean A
|
|
|
23 |
1 |
p. e14-e15
|
artikel
|
| 15 |
Correction to Lancet Oncol 2021; 22: 1518–29
|
|
|
|
23 |
1 |
p. e16
|
artikel
|
| 16 |
Correction to Lancet Oncol 2021; 22: e540
|
|
|
|
23 |
1 |
p. e16
|
artikel
|
| 17 |
COVID-19 pandemic to lead to thousands of additional UK lung cancer deaths
|
Wilkinson, Emma
|
|
|
23 |
1 |
p. 20
|
artikel
|
| 18 |
Dabrafenib plus trametinib in patients with BRAF V600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
|
Wen, Patrick Y
|
|
|
23 |
1 |
p. 53-64
|
artikel
|
| 19 |
Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era
|
Abid, Muhammad Bilal
|
|
|
23 |
1 |
p. 16-18
|
artikel
|
| 20 |
European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer
|
Meattini, Icro
|
|
|
23 |
1 |
p. e21-e31
|
artikel
|
| 21 |
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
|
Naranbhai, Vivek
|
|
|
23 |
1 |
p. 172-184
|
artikel
|
| 22 |
ICGC-ARGO precision medicine: familial matters in pancreatic cancer
|
Milella, Michele
|
|
|
23 |
1 |
p. 25-26
|
artikel
|
| 23 |
KRAS G12C inhibition in colorectal cancer
|
Pfeiffer, Per
|
|
|
23 |
1 |
p. 10-11
|
artikel
|
| 24 |
Leaders of change: does it take a patient to put patients first?
|
The Lancet Oncology,
|
|
|
23 |
1 |
p. 1
|
artikel
|
| 25 |
Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study
|
Reig, Maria
|
|
|
23 |
1 |
p. 4-6
|
artikel
|
| 26 |
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
|
Yau, Thomas
|
|
|
23 |
1 |
p. 77-90
|
artikel
|
| 27 |
Postoperative radiotherapy in resected N2 non-small-cell lung cancer: Lung ART
|
Hendriks, Lizza E L
|
|
|
23 |
1 |
p. 8-9
|
artikel
|
| 28 |
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial
|
Le Pechoux, Cecile
|
|
|
23 |
1 |
p. 104-114
|
artikel
|
| 29 |
Prioritising access to cancer drugs
|
Puyat, Corinna Victoria M
|
|
|
23 |
1 |
p. e2
|
artikel
|
| 30 |
Prioritising access to cancer drugs
|
Elliott, Mitchell J
|
|
|
23 |
1 |
p. e1
|
artikel
|
| 31 |
Radiographic progression-free survival in the ACIS trial for prostate cancer
|
Gilboa, Shai
|
|
|
23 |
1 |
p. e3
|
artikel
|
| 32 |
Radiographic progression-free survival in the ACIS trial for prostate cancer
|
Tannock, Ian F
|
|
|
23 |
1 |
p. e4
|
artikel
|
| 33 |
Radiographic progression-free survival in the ACIS trial for prostate cancer – Authors' reply
|
Saad, Fred
|
|
|
23 |
1 |
p. e5-e6
|
artikel
|
| 34 |
63rd ASH Annual Meeting and Exposition
|
Lai, Cheryl
|
|
|
23 |
1 |
p. e19-e20
|
artikel
|
| 35 |
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
|
Yau, Christina
|
|
|
23 |
1 |
p. 149-160
|
artikel
|
| 36 |
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial
|
Mauz-Körholz, Christine
|
|
|
23 |
1 |
p. 125-137
|
artikel
|
| 37 |
Risk-based lung cancer screening eligibility criteria: towards implementation
|
ten Haaf, Kevin
|
|
|
23 |
1 |
p. 13-14
|
artikel
|
| 38 |
Rs708113 in WNT3A-WNT9A and hepatocellular carcinoma risk
|
Stickel, Felix
|
|
|
23 |
1 |
p. 14-16
|
artikel
|
| 39 |
San Antonio Breast Cancer Symposium 2021
|
Reeves, Cheryl
|
|
|
23 |
1 |
p. e18
|
artikel
|
| 40 |
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer
|
Rizzo, Alessandro
|
|
|
23 |
1 |
p. e11
|
artikel
|
| 41 |
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer – Author's reply
|
Yoo, Changhoon
|
|
|
23 |
1 |
p. e12
|
artikel
|
| 42 |
Shamim Nabuuma Kaliisa: survivor takes on cancer with AI
|
Makoni, Munyaradzi
|
|
|
23 |
1 |
p. 22-23
|
artikel
|
| 43 |
Should brachytherapy be added to external beam radiotherapy for prostate cancer?
|
Gomez-Iturriaga, Alfonso
|
|
|
23 |
1 |
p. 23-25
|
artikel
|
| 44 |
Sotorasib for previously treated colorectal cancers with KRAS G12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
|
Fakih, Marwan G
|
|
|
23 |
1 |
p. 115-124
|
artikel
|
| 45 |
Study of the Veterans Affairs Health Care System highlights the impact of COVID-19 on cancer diagnoses in the USA
|
Parker, Stephanie
|
|
|
23 |
1 |
p. 21
|
artikel
|
| 46 |
Targeting BRAF-mutant glioma: reflections on the ROAR trial
|
Peters, Katherine B
|
|
|
23 |
1 |
p. 3-4
|
artikel
|
| 47 |
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019
|
|
|
|
23 |
1 |
p. 27-52
|
artikel
|
| 48 |
The tumours and the three bumps
|
Bousson, Valérie
|
|
|
23 |
1 |
p. e44
|
artikel
|
| 49 |
USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study
|
Tammemägi, Martin C
|
|
|
23 |
1 |
p. 138-148
|
artikel
|
| 50 |
WHO and St Jude Children's Research Hospital announce childhood cancer medicines initiative
|
Burki, Talha Khan
|
|
|
23 |
1 |
p. e17
|
artikel
|
Tijdschrift beschrijving